CHARLOTTE, NC AND BEVERLY HILLS, CA.—Tomosoft Technologies, LLC, innovators in radiation dose reduction software for medical diagnostic imaging, today announced that it has been awarded a $244,000 grant under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grant, which targets therapeutic discovery projects that show potential to result in new therapies to treat areas of unmet medical need or treat chronic or acute diseases and conditions potentially resulting in reduced health care costs.
”We are delighted that the potential advantages of our proprietary software have been recognized through the award of this grant to help support its development for mitigating risks associated with medical imaging while not compromising image quality. We are addressing a major public health problem and this grant will help us continue further refining the technology to its commercial endpoint,” commented Michael Sinsheimer, President of Tomosoft Technologies.
About Tomosoft’s Dose Reduction Software
The TomoSoft image reconstruction technique enables for tomographic reconstruction using only a fraction of projections and x-ray source flux, and consequently a fraction of the radiation dose, relative to existing techniques. The methodology, termed Equally-Sloped Tomography (EST), is a general technique, applicable to existing medical CT scanners and procedures, which under ultra low dose acquisitions, solves for missing projection data and minimizes the noise to result in reconstructions of unprecedented accuracy. The technology was developed and exclusively licensed from the University of California at Los Angeles (UCLA).
Currently, the method has been implemented on clinical scanners at UCLA in image quality phantom studies, and the results show significant radiation dose reductions relative to current methods while achieving the same image quality as conventional full-dose reconstructions, as quantified by such metrics as resolution, contrast, and geometrical fidelity.
About the Qualifying Therapeutic Discovery Project
The Qualifying Therapeutic Discovery Project (QTDP) is provided under new section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010 (P.L. 111-148). The credit is a tax benefit targeted to therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, reduce the long-term growth of health care costs in the United States, or significantly advance the goal of curing cancer within 30 years. Allocation of the credit also takes into consideration which projects show the greatest potential to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in life, biological and medical sciences. The Therapeutic Discovery Project tax credit is only available to companies with 250 or less employees. The credit covers up to 50 percent of a qualified investment. To provide an immediate boost to U.S. biomedical research, the credit is available for qualified investments made or to be made in 2009 and 2010.
CONTACT INFORMATION
Mike Sinsheimer, MBA, MHA msinsheimer@carolina.rr.com 704-773-7652
